Since there are no known mutations in the PI3K/mTOR signaling cascade in A549 cells [30], it is likely, that the different tumor entity is the main reason for the different sensitivity towards dual PI3K/mTOR inhibition. The gene discussed is MTOR; the disease is neoplasm.